ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TLRY vs DFTX // EV/EBITDA & P/E VALUATION

Tilray Brands Inc. (NASDAQ) VS. Definium Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TLRY 3 — DFTX 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLRY VS. DFTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TLRY DFTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 28.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -3.90% -32.20% +28.30 TLRY /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -17.72% -3.84% -13.88 DFTX /fcf-yield <GO>
Operating Margin -6.90% -11.60% +4.70 TLRY /operating-margins <GO>
Net Profit Margin -13.30% -12.90% -0.40 DFTX /net-margins <GO>
Revenue Growth (YoY) 11.50% 5.50% +6.00 TLRY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 26.00 -25.80 DFTX /balance-sheet <GO>
Piotroski F-Score Quality 5/9 5/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.8 55.4 -29.60 DFTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 33.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $390.2M $5.10B -$4.71B DFTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TLRY REV DFTX REV TLRY GROSS % DFTX GROSS % TLRY FCF DFTX FCF
FY 2025 $915.5M $0 28.4% — -$69.1M -$131.6M
FY 2024 $821.3M $0 29.3% — -$94.6M -$79.1M
FY 2023 $788.9M $0 — — -$30.9M -$64.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLRY // BETA —
DFTX // BETA 1.08